"Immunization, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
| Descriptor ID |
D007117
|
| MeSH Number(s) |
E02.095.465.425.400.485 E05.478.550.550
|
| Concept/Terms |
Immunization, Secondary- Immunization, Secondary
- Immunizations, Secondary
- Secondary Immunizations
- Immunization, Booster
- Booster Immunization
- Booster Immunizations
- Immunizations, Booster
- Secondary Immunization
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Secondary".
This graph shows the total number of publications written about "Immunization, Secondary" by people in this website by year, and whether "Immunization, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization, Secondary" by people in Profiles.
-
Nixon DF, Schwartz RE, Ndhlovu LC. Booster vaccines for COVID-19 vaccine breakthrough cases? Lancet. 2022 03 26; 399(10331):1224.
-
Tiwari S, Dutt TS, Chen B, Chen M, Kim J, Dai AZ, Lukose R, Shanley C, Fox A, Karger BR, Porcelli SA, Chan J, Podell BK, Obregon-Henao A, Orme IM, Jacobs WR, Henao-Tamayo M. BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis. Vaccine. 2020 10 21; 38(45):7156-7165.
-
Choudhury SA, Matin F. Subnormal and waning immunity to tetanus toxoid in previously vaccinated HIV-infected children and response to booster doses of the vaccine. Int J Infect Dis. 2013 Dec; 17(12):e1249-51.
-
Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP, Khizer S, Barrett C, Quaye O, Mijatovic-Rustempasic S, Gautam R, Bowen MD, Moore J, Tate JE, Parashar UD, V?zquez M. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics. 2013 Jul; 132(1):e25-33.
-
Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011 Sep 15; 204(6):845-53.
-
Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine. 2009 Feb 11; 27(7):1040-9.
-
Alavian SM, Izadi M, Zare AA, Lankarani MM, Assari S, Vardi MM. Survey of the level of anti-HBs antibody titer in vaccinated Iranian general dentists. Spec Care Dentist. 2008 Nov-Dec; 28(6):265-70.
-
Choudhury SA, Mishreki NK. Subnormal immunity to Hemophilus influenzae type b (Hib) in previously vaccinated human immunodeficiency virus-infected children 59 months of age or older and response to booster doses of the conjugate vaccine. Clin Pediatr (Phila). 2004 Nov-Dec; 43(9):831-5.
-
Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis. 1998 May; 177(5):1352-7.